Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Trastuzumab Prior Auth | Open…
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Herceptin Products (Trastuzumab)

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for trastuzumab reference, biosimilar, and subcutaneous products provided under the medical benefit for MassHealth members. It establishes coverage criteria for HER2-overexpressing breast cancer, HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, and RAS wild-type HER2-positive unresectable or metastatic colorectal cancer.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyHerceptin Products (Trastuzumab)
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateJanuary 4, 2027
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for listed trastuzumab products under the medical benefit.
    SourceLink
    POLICY UPDATE CHANGES

    Hercessi (trastuzumab-strf) was added as a covered trastuzumab product in the policy criteria.

    Kanjinti (trastuzumab-anns) was added as the step-through preferred product for other trastuzumab products.

    The clinical rationale requirement for non-preferred trastuzumab products was clarified.

    The policy was reformatted and its references were updated.

    3Covered disease indications
    8Trastuzumab products listed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    KanjintiPreferred product
    12 monthsApproval duration
    MedicalBenefit

    Covered Indications

    Breast Cancer

    Coverage may be granted when either the new-member continuation requirement or all applicable breast cancer criteria are met.

    Breast cancer coverage pathways

    • New-member continuation: The member has been enrolled in the plan for 90 days or less, and medical records document that the member is currently receiving treatment with the requested drug. Treatment obtained as samples or through a manufacturer's patient assistance program does not satisfy this requirement.
    • Breast cancer criteria

      • Core criteria: Diagnosis of HER2-overexpressing breast cancer; the prescriber is an oncologist; and appropriate dosing is documented, including the member's weight.
      • Requested product requirements

        • Preferred product: The requested product is Kanjinti (trastuzumab-anns).
        • Non-preferred product: The requested product is Herceptin (trastuzumab), Hercessi (trastuzumab-strf), Herzuma (trastuzumab-pkrb), Ogivri (trastuzumab-dkst), Ontruzant (trastuzumab-dttb), or Trazimera (trastuzumab-qyyp); medical records document inadequate response, an adverse reaction, or a contraindication to Kanjinti; and clinical rationale explains why the requested product is expected to provide a different clinical outcome than Kanjinti.

    Metastatic Gastric or GEJ Adenocarcinoma

    Coverage may be granted when all applicable metastatic gastric or gastroesophageal junction adenocarcinoma criteria are met.

    Metastatic gastric or GEJ adenocarcinoma criteria

    • ONE of the following requested agents

      • Herceptin (trastuzumab).
      • Hercessi (trastuzumab-strf).
      • Herzuma (trastuzumab-pkrb).
      • Kanjinti (trastuzumab-anns).
      • Ogivri (trastuzumab-dkst).

    Unresectable or Metastatic Colorectal Cancer

    Coverage may be granted when all applicable unresectable or metastatic colorectal cancer criteria are met.

    Unresectable or metastatic colorectal cancer criteria

    • ONE of the following requested agents

      • Herceptin (trastuzumab).
      • Hercessi (trastuzumab-strf).
      • Herzuma (trastuzumab-pkrb).
      • Kanjinti (trastuzumab-anns).
      • Ogivri (trastuzumab-dkst).

    Continuation Therapy

    Resubmission by the prescriber will infer a positive response to therapy.

    Continuation therapy: The prescriber must resubmit the request for continuation; resubmission infers a positive response to therapy.

    Initial Authorization Requirements

    Breast Cancer Initial Therapy

    Authorization may be granted when all applicable breast cancer initial-therapy criteria are met.

    Breast cancer initial therapy

    • Diagnosis of HER2-overexpressing breast cancer; the prescriber is an oncologist; and appropriate dosing is documented, including the member's weight.
    • Requested product requirements

      • The requested product is Kanjinti (trastuzumab-anns).
      • The requested product is Herceptin (trastuzumab), Hercessi (trastuzumab-strf), Herzuma (trastuzumab-pkrb), Ogivri (trastuzumab-dkst), Ontruzant (trastuzumab-dttb), or Trazimera (trastuzumab-qyyp); medical records document inadequate response, an adverse reaction, or a contraindication to Kanjinti; and clinical rationale explains why the requested product is expected to provide a different clinical outcome than Kanjinti.

    Reauthorization Requirements

    Continuation Authorization

    Resubmission by the prescriber will infer a positive response to therapy.

    Continuation authorization: The prescriber must resubmit the request for continuation; resubmission infers a positive response to therapy.

    Preferred Product Sequence

    StepProductCoverage requirement
    1Kanjinti (trastuzumab-anns)Preferred trastuzumab product; use first.
    After Step 1Herceptin (trastuzumab), Hercessi (trastuzumab-strf), Herzuma (trastuzumab-pkrb), Ogivri (trastuzumab-dkst), Ontruzant (trastuzumab-dttb), or Trazimera (trastuzumab-qyyp)Requires medical records documenting inadequate response, adverse reaction, or contraindication to Kanjinti, plus clinical rationale explaining why the requested product is expected to provide a different clinical outcome than Kanjinti.

    Authorization Duration

    Quantity limits
    Initial approval duration12 months
    Reauthorization duration12 months
    Applies toAll covered trastuzumab products

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for the listed trastuzumab products under the MassHealth UPPL. Coverage is provided under the medical benefit.

    • Herceptin (trastuzumab)
    • Herceptin Hylecta (trastuzumab-hyaluronidase-oysk)
    • Hercessi (trastuzumab-strf)
    • Herzuma (trastuzumab-pkrb)
    • Kanjinti (trastuzumab-anns)
    • Ogivri (trastuzumab-dkst)
    • Ontruzant (trastuzumab-dttb)
    • Trazimera (trastuzumab-qyyp)
    Step Therapy

    Kanjinti Preferred; Exception Required

    Kanjinti (trastuzumab-anns) is the preferred trastuzumab product. Requests for other listed trastuzumab products require documentation supporting an exception to Kanjinti.

    Trastuzumab Overview

    Trastuzumab is a HER2/neu receptor antagonist used for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. FDA-approved trastuzumab biosimilars have the same indications as the reference product, and NCCN considers an FDA-approved biosimilar an appropriate substitute for the reference product. The policy also covers trastuzumab in combination with Tukysa (tucatinib) for RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer when the applicable criteria are met.

    Preferred and Non-Preferred Trastuzumab Products

    Billing Rule

    Kanjinti is preferred over other trastuzumab products

    Kanjinti (trastuzumab-anns) is the preferred trastuzumab product. Herceptin, Hercessi, Herzuma, Ogivri, Ontruzant, and Trazimera require documentation of inadequate response, adverse reaction, or contraindication to Kanjinti plus clinical rationale that the requested product is expected to provide a different clinical outcome.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyHerceptin Products (Trastuzumab)
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateJanuary 4, 2027
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for listed trastuzumab products under the medical benefit.
    SourceLink
    On This Page
    Covered IndicationsInitial Authorization RequirementsReauthorization RequirementsPreferred Product SequenceAuthorization DurationPrior Authorization and DocumentationTrastuzumab OverviewPreferred and Non-Preferred Trastuzumab Products
    Ontruzant (trastuzumab-dttb).
  1. Trazimera (trastuzumab-qyyp).
  2. Clinical criteria: Diagnosis of HER2-overexpressing metastatic gastric or GEJ adenocarcinoma; the prescriber is an oncologist; appropriate dosing is documented, including the member's weight; and the requested agent will be used in combination with chemotherapy.
  3. Preferred-product pathway

    • The requested agent is Kanjinti (trastuzumab-anns).
    • The requested agent is Herceptin (trastuzumab), Hercessi (trastuzumab-strf), Herzuma (trastuzumab-pkrb), Ogivri (trastuzumab-dkst), Ontruzant (trastuzumab-dttb), or Trazimera (trastuzumab-qyyp), and medical records document inadequate response, an adverse reaction, or a contraindication to Kanjinti and clinical rationale explaining why the requested product is expected to provide a different clinical outcome than Kanjinti.
  4. Ontruzant (trastuzumab-dttb).
  5. Trazimera (trastuzumab-qyyp).
  6. Clinical criteria: Diagnosis of RAS wild-type (WT), HER2-positive unresectable or metastatic colorectal cancer; the prescriber is an oncologist; appropriate dosing is documented, including the member's weight; and the requested agent will be used in combination with Tukysa (tucatinib).
  7. Prior chemotherapy requirement

    • The member has had an inadequate response or adverse reaction to one of the following regimens: CAPEOX, FOLFOX, FOLFIRI, FOLFOXIRI, FOLFIRINOX, irinotecan-based therapy, or oxaliplatin-based therapy.
    • The member has a contraindication to all of the following regimens: CAPEOX, FOLFOX, FOLFIRI, FOLFOXIRI, FOLFIRINOX, irinotecan-based therapy, and oxaliplatin-based therapy.
  8. Preferred-product pathway

    • The requested agent is Kanjinti (trastuzumab-anns).
    • The requested agent is Herceptin (trastuzumab), Hercessi (trastuzumab-strf), Herzuma (trastuzumab-pkrb), Ogivri (trastuzumab-dkst), Ontruzant (trastuzumab-dttb), or Trazimera (trastuzumab-qyyp), and medical records document inadequate response, an adverse reaction, or a contraindication to Kanjinti and clinical rationale explaining why the requested product is expected to provide a different clinical outcome than Kanjinti.
    • For breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma, document inadequate response, an adverse reaction, or a contraindication to Kanjinti and why the requested non-preferred product is expected to provide a different clinical outcome.
    • For unresectable or metastatic colorectal cancer, document inadequate response, an adverse reaction, or a contraindication to Kanjinti and why the requested non-preferred product is expected to provide a different clinical outcome.
    Documentation Required

    Document Current Treatment for New Members

    For a member who has been covered by the plan for 90 days or less, submit medical records showing that the member is currently receiving treatment with the requested drug. This continuation documentation requirement does not apply when the product was obtained as samples or through a manufacturer’s patient assistance program.

    Documentation Required

    Submit Clinical Records and Dosing Information

    Submit complete clinical records supporting the requested indication and regimen, including the diagnosis, prescriber specialty, member weight, and appropriate weight-based dosing. Include indication-specific treatment details and combination therapy information when applicable.

    • Breast cancer: HER2-overexpressing breast cancer; prescriber must be an oncologist; document appropriate dosing with member weight.
    • Metastatic gastric or GEJ adenocarcinoma: HER2-overexpressing metastatic gastric or GEJ adenocarcinoma; prescriber must be an oncologist; document appropriate dosing with member weight and use in combination with chemotherapy.
    • Unresectable or metastatic colorectal cancer: RAS wild-type, HER2-positive disease; prescriber must be an oncologist; document appropriate dosing with member weight, required prior-regimen history, and use in combination with Tukysa (tucatinib).
    Documentation Required

    Support a Non-Preferred Product Exception

    When requesting a non-preferred trastuzumab product instead of Kanjinti, submit records documenting an inadequate response, adverse reaction, or contraindication to Kanjinti, together with clinical rationale explaining why the requested product is expected to produce a different clinical outcome.

    • This exception documentation applies to Herceptin, Hercessi, Herzuma, Ogivri, Ontruzant, and Trazimera for the applicable breast cancer, metastatic gastric or GEJ adenocarcinoma, and colorectal cancer indications.
    • For colorectal cancer, also document inadequate response or an adverse reaction to one, or a contraindication to all, of CAPEOX, FOLFOX, FOLFIRI, FOLFOXIRI, FOLFIRINOX, irinotecan-based therapy, or oxaliplatin-based therapy.
    Denial Risk

    Indication Criteria Must Be Met

    Requests may be denied when the diagnosis, prescriber, dosing, or other indication-specific requirements are not documented or are not met.

    • Breast cancer requires HER2-overexpressing breast cancer and an oncologist prescriber.
    • Metastatic gastric or GEJ adenocarcinoma requires HER2-overexpressing metastatic disease, an oncologist prescriber, appropriate dosing, and use with chemotherapy.
    • Colorectal cancer requires RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer, an oncologist prescriber, appropriate dosing, required prior-regimen documentation, and combination use with Tukysa (tucatinib).
    Denial Risk

    Missing Kanjinti Exception Documentation

    A request for a non-preferred trastuzumab product may be denied when the required Kanjinti exception records are absent. The clinical rationale must explain why the requested product is expected to provide a different outcome, not merely identify a preference for that product.

    • Document inadequate response, adverse reaction, or contraindication to Kanjinti.
    • Explain the expected different clinical outcome with the requested non-preferred product.
    Denial Risk

    Colorectal Cancer Criteria Required

    For unresectable or metastatic colorectal cancer, coverage may be denied when the disease is not documented as RAS wild-type and HER2-positive, or when it is not unresectable or metastatic colorectal cancer.

    • Document RAS wild-type (WT), HER2-positive unresectable or metastatic colorectal cancer.
    • Document inadequate response or adverse reaction to one, or contraindication to all, of CAPEOX, FOLFOX, FOLFIRI, FOLFOXIRI, FOLFIRINOX, irinotecan-based therapy, or oxaliplatin-based therapy.
    • Document combination treatment with Tukysa (tucatinib), as applicable.